Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Cellular Biomedicine Accepts $383 Million Management-led Privatization Offer

publication date: Aug 12, 2020

Cellular Biomedicine, a biopharma headquartered in Maryland with operations in Shanghai, signed a definite $383 million go-private merger agreement with a company formed by management and an investment syndicate. CBMG is developing immunotherapies for cancer and stem cell therapies for degenerative diseases. The agreement was set at $19.75 per share, slightly higher than the original $19.50 per share offered last fall and 31% above the company's average price over the last 30 days. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital